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Objective: Although shown to provide a beneﬁt in aspergillosis treatment, the
administration of voriconazole ( VCZ) became limited by frequent photosensitivity
(PS). However, risk factors to undergo PS are unknown.
Methods: This study was conducted from April 2003, date of VCZ availability, to
December 2005, in one tertiary CF reference centre. The medical ﬁles of children
(age <18 y; n = 72) and adults (n = 63) were reviewed, and those who were given
VCZ were selected. Non parametric tests, Chi2-tests and logistic regression were
used for statistics.
Results: 31 patients (21.4%) were given VCZ and 18 (58%) reported VCZ-
related photosensitivity. There was no difference between pediatric and adult
populations. DF508/DF508 was strongly associated with the occurrence of PS,
independently of pancreatic insufﬁciency (Table). Univariate analyses showed that
DF508/DF508 increased (OR= 24[2.5−2.0], p = 0.005) and age slightly decreased
(OR= 0.99 [0.98−1.0], p = 0.04) the risk of PS. Multivariate analyses retained only
DF508/DF508 genotype as a a risk factor of PS (p = 0.009).
Characteristics of PS and no PS populations
Photosensitivity,
n = 18
No photosensitivity
n = 13
p
Age (y) 157 236 0.08
Gender (M/F) 10/8 5/8 NS
DF508/DF508 12 (66.6%) 1 (7.7%) 0.004
DF508/other 5 (27.8%) 11 (84%)
Other/other 1 (5.6%) 1 (7.7%)
Pancreatic insufﬁciency 17 (94.5%) 10 (76.5%) NS
Daily dose (mg/kg) 8.6 16.7 0.10
Time of drug exposure (mo) 11.1 8.7 NS
Conclusion: Photosensitivity should be expected in DF508/DF508 CF patients,
leading to frequent treatment interruption. The mechanism of VCZ-related PS
remains unknown.
